Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?
2026-525909-13-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2026
- Modality
- Peptides, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of liraglutide and 23-valent pneumococcal polysaccharide vaccine in type 2 diabetes mellitus (T2DM) and pneumococcal disease (3 arms), sponsored by Radboud University Medical Center. Planned start Oct 2026; status: authorised.
02
Drugs
liraglutide23-valent pneumococcal polysaccharide vaccine
03
Conditions
type 2 diabetes mellitus (T2DM)pneumococcal disease
Beyond the preview
Go deeper on 2026-525909-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525909-13-00.